Fondation Franc.Cancerologie Digestive — Sponsor Intelligence | 19 EU Trials

Filter these 19 trials by condition, phase, country and more.

Open in Search →

19 Registered trials

7 Recruiting

12 Completed trials

5 Countries active

31 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 3 Phase II/III: 4 Phase II: 12

Oversight events:

1 temporary halt 2 urgent safety measures 2 unexpected events across 3 trials

View oversight register →

100%

12 of 12 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer 1

Top IMPs

OXALIPLATIN 6 CAPECITABINE 5 FOLINIC ACID 5 FLUOROURACIL 4 BEVACIZUMAB 3 ATEZOLIZUMAB 2 FRUQUINTINIB 2 GEMCITABINE 2 PACLITAXEL 2 PANITUMUMAB 2 CETUXIMAB 1 CISPLATIN 1

All trials

19 total

PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending

2024-519753-11-00 Phase II 1 country FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OX…
Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed b… Recruiting

2024-518143-38-00 Phase II/III 1 country IRINOTECAN
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 Phase II 1 country BEVACIZUMAB; FRUQUINTINIB
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 Phase III 3 countries FRUQUINTINIB; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 Phase II 4 countries FLUOROURACIL; FOLINIC ACID; PANITUMUMAB
Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemothera… Recruiting

2024-517204-11-00 Phase II 1 country ATEZOLIZUMAB; BEVACIZUMAB; CAPECITABINE; OXALIPLATIN
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 Phase II 1 country BEVACIZUMAB; CAPECITABINE; OXALIPLATIN; PEMBROLIZUMAB
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING I… Recruiting

2024-514107-34-00 Phase II 1 country CETUXIMAB; ENCORAFENIB
PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended

2025-521302-17-00 Phase II/III 1 country CISPLATIN; GEMCITABINE; RILVEGOSTOMIG
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first… Ended

2024-518553-41-00 Phase III 2 countries OXALIPLATIN
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 Phase III 1 country
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Phase II/III 1 country ATEZOLIZUMAB; IPILIMUMAB
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 Phase II 2 countries CAPECITABINE; FLUOROURACIL; FOLINIC ACID; LEVOLEUCOVORIN; OXALIPLATIN
PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advance… Ended

2024-513515-27-00 Phase II 1 country PACLITAXEL; RAMUCIRUMAB
FFCD 1605- OPTIPRIME: A phase II study evaluating FOLFOX + panitumumab according to a ‘stop-and-go’ strategy with a reintroduction loop afte… Ended

2024-518740-20-00 Phase II 2 countries CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB
MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY … Ended

2024-517362-41-00 Phase II 1 country FOLINIC ACID
Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oe… Ended

2024-515221-29-00 Phase II/III 1 country
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Phase II 1 country CAPECITABINE; DURVALUMAB
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 Phase II 1 country DOMVANALIMAB; ZIMBERELIMAB

Showing 1–19 of 19 trials

← All sponsors A–Z